Managed Care Companies Predicting the “Worst of Two Worlds”

Incorporating MCO Utilization Estimates into Provider Valuations

Commentary from publicly traded Managed Care Organizations (MCOs) regarding their insurance spend expectations can be an excellent source of macroeconomic data for health care valuation professionals when projecting performance for provider entities. Now halfway through 2021, MCOs are generally factoring continued COVID costs coupled with higher non-COVID utilization into their full year 2021 earnings estimates: the worst of two worlds from the MCO’s perspective.

Why it Matters

  • Since providers earn the dollars that MCOs spend, these predictions, (if accurate) are a good macroeconomic source to assist when developing a forecast of provider revenue in the near term by payer and population segment.
  • The medical loss ratio (MLR) reflects the percentage of MCO premiums paid to providers due to insured patient utilization of health care services. This ratio was lower in 2020 compared to prior years due to less overall non-COVID patient utilization from deferred, delayed, or canceled services and patient hesitancy.

Average Medical Loss Ratios

 

  • For the second half of 2021, MCO commentary indicates that they anticipate continued payout for patients with COVID. However, unlike the low levels experienced in 2020, MCOs also expect commercial non-COVID utilization to be at or above the 2019 baseline. Comparatively, the Medicare Advantage patient non-COVID utilization is expected to be below the 2019 baseline, and Medicaid patient non-COVID utilization is expected to be below Medicare Advantage.

For Example:

  • Overall, MCOs do not expect the strong performance (i.e. low MLR) of 2020 to continue into 2021. Examples of MCO commentary regarding 2nd quarter actual utilization, COVID estimates for the second half of 2021, and non-COVID utilization estimates for the second half of 2021 are summarized below:

Managed Care Organization

Historical Q2 2021

Rest of Year

Observations

COVID Estimates

Non-COVID Estimates

 

Cigna

*Ongoing COVID costs above expectations

*Non-COVID returned faster than expected

*Medicare Advantage below expectation

*Lower than first half ‘21

*Commercial at baseline

*Mental health and surgery above baseline

*Radiology and ER below baseline

 

Anthem

*Non-COVID utilization up from depressed levels

*Medicaid below baseline

*Overall utilization above baseline

*Higher than first half ‘21

*Above baseline in 2nd half ‘21

*Inpatient and ER below baseline

*Physicians and outpatient above

*Unclear if patients will defer because of Delta


CVS Health / Aetna

*Higher than expected COVID costs

*Vaccine revenue slightly down

*Slightly higher than first half ‘21

*Return to baseline by 4th quarter

*Inpatient, lab, behavioral elevated

*ER depressed


UnitedHealth

*COVID testing and treatment highest in April

*Commercial utilization marginally above baseline

*Government utilization marginally below

*No change

*Utilization trending higher

*Inpatient volume near baseline

*Physician visits trending up

Note: Baseline = adjusted 2019 utilization

Health Care Valuation Takeaways

  • A health care valuation professional should analyze and incorporate economic data from a wide variety of sources. Analyzing MCO expectations for utilization is an excellent source of macroeconomic data. If MCOs are pessimistic about their spend (i.e. higher MLRs), this conversely could be a positive macroeconomic indicator of higher revenue expectations for provider entities.
  • MCO commentary seems to indicate that many providers have mitigated patient fears about returning to the health care system, and have succeeded in insulating non-COVID volume. Providers have successfully implemented COVID protocols that have allowed the non-COVID business (especially the commercial segment) to return to pre-pandemic baseline levels in many cases.
  • According to MCO commentary, the success of providers bringing back non-COVID core volume is payer class dependent. MCOs report commercial non-COVID volume back to or close to baseline 2019 volumes. Medicare and Medicaid volume remain below baseline, possibly reflecting hesitancy of returning to the health care system by a portion of this population.

Dig Deeper

For Kaiser Family Foundation’s analysis of insurance company performance during the pandemic, click here:

For information about health care valuations for your business, contact Weaver. We're here to help.

© 2021


This is one in a series of related health care valuation posts: